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Abstract
A woman typically presents for genetic counselling because she
has a strong family history and is interested in knowing the
probability she will develop disease in the future; that is, her
absolute risk. Relative risk for a given factor refers to risk compared
with either population average risk (sense a), or risk when not
having the factor, with all other factors held constant (sense b). Not
understanding that these are three distinct concepts can result in
failure to correctly appreciate the consequences of studies on
clinical genetic testing. Several studies found that the frequencies
of mutations in ATM, BRIP1, PALB2 and CHEK2 were many times
greater for cases with a strong family history than for controls. To
account for the selected case sampling (ascertainment), a
statistical model that assumes that the effect of any measured
variant multiplies the effect of unmeasured variants was applied.
This multiplicative polygenic model in effect estimated the relative
risk in the sense b, not sense a, and found it was in the range of
1.7 to 2.4. The authors concluded that the variants are “low pene-
trance”. They failed to note that their model fits predicted that, for
some women, absolute risk may be as high as for BRCA2 mutation
carriers. This is because the relative risk multiplies polygenic risk,
and the latter is predicted by family history. Therefore, mutation
testing of these genes for women with a strong family history,
especially if it is of early onset, may be as clinically relevant as it is
for BRCA1 and BRCA2.
Introduction
When an unaffected woman presents for breast-cancer
related genetic counselling it is typically because her family
history of the disease is unusually strong. Her primary interest
is in knowing the probability that she will develop cancer in the
future. That is, she is interested in her absolute risk of disease.
Epidemiologists use the term ‘relative risk’, as a measure of
‘increased’ risk, when they are referring to either: a woman’s
risk divided by the risk to an average woman in the population
(sense a); or the risk ratio or odds ratio associated with a
particular genetic or environmental risk factor, which is how
much having that factor multiplies a woman’s risk compared
to if they did not have that factor, with all other factors held
constant (sense b).
Not understanding that these are three distinct concepts and
measures of risk (absolute risk, relative risk in the sense a,
relative risk on the sense b) can result in a failure to correctly
appreciate or communicate the consequences of studies on
genetic testing in the clinical setting. We shall illustrate this
by reference to recently published papers on mutations in
ATM, BRIP1 and PALB2, and a similar paper on a founder
mutation in CHEK2.
Studies of familial cases and controls
At least five papers [1-5] have recently reported on studies of
women with breast cancer who have a strong cancer family
history not known to be due to germline mutations in BRCA1
or BRCA2 (familial cases; see group A in Figure 1), screen-
ing them variously for mutations in ATM, BRIP1 or PALB2, or
for the 1100delC mutation in CHEK2. Comparison groups of
unaffected women from the general population were similarly
screened (controls; see group B+D in Figure 1).
Each study found that the frequency of mutations for the
familial cases was substantially higher than for the controls
(Table 1). For ATM, BRIP1 and PALB2, this relative frequency
(RF) was higher by about seven-fold or more (though with
wide confidence intervals). For the three UK studies [1-3], in
total, 31 mutations were found from 2,578 tests of familial
cases (1.2%) compared with 4 mutations from 3,686 tests of
controls (0.1%), an overall RF of 11-fold. A Finnish study
found the c.1592delT PALB2 mutation in 3 of 113 familial
cases (2.7%) and 6 of 2,501 controls (0.2%), and again RF
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was 11-fold [4]. The CHEK2 1100delC mutation was found
in 55 of 1,071 familial cases (5.1%) compared with 18 of
1,620 controls (1.1%) [5]. For each study the authors con-
cluded, we believe correctly, that mutations in the relevant
genes were associated with an increased risk of breast
cancer. The question of clinical significance is: what are the
‘risks’ for women found to have these rare variants?
It is not a simple matter to directly interpret the data above.
The observed ratios of carriage between cases from multiple-
case families and population controls do not estimate relative
risks in sense a or b since one does not know the rate of
carriage in group C in Figure 1 and the usual Bayes’ theorem
calculation does not apply.
To try to overcome this problem, in each instance the authors
fitted a multiplicative polygenic model [6] (see below). This
assumes that there are many genes involved with breast
cancer risk and they together determine a woman’s polygenic
absolute risk. The effect of any single measured genetic
variant is then assumed to multiply each woman’s polygenic
risk by a constant factor, relative risk (RR). RR, therefore,
represents the effect of the measured variant on risk
averaged over the population, and would be the relative risk
estimate one would obtain from the ratio of variant frequency
for unselected cases to that for unselected controls.
Table 1 shows that applying this model led to estimates of
RR between 2.0 and 2.4 for the genes ATM, BRIP1, and
PALB2  [1-3], and 1.7 for the 1100delC CHEK2 mutation
[5]. This relative risk, however, references a particular woman’s
absolute risk to her individual, unknown polygenic risk, or
(approximately) the average carrier’s risk to the population
average risk. It does not mean that all carriers are at RR times
the population average risk. This important point does not
appear to have been appreciated.
The authors of these four papers [1-3,5] have failed to
recognise that their analyses predict that mutations in these
genes, when detected in women with a strong family history,
Figure 1
The proportion of mutation carriers has been measured for women in
group A (familial cases) and for women in group B+D (controls). The
proportion of mutation carriers is not known for cases without a family
history (group C) and, therefore, is not known for women in group
A+C. The authors have tried to estimate, in effect, the relative
proportion of carriers between groups A+C and B+D, so as to
estimate the relative risk associated with having a mutation for the
average woman. To do so they have invoked a multiplicative polygenic
model. Whatever model is used, however, the absolute risk prediction
for women with a strong family history will be about the same. Although
the absolute risk prediction for women without a strong family history
may well differ depending on the assumptions of the fitted model, in
practice this may not matter because only women with a strong family
history are likely to be tested for these mutations.
Table 1
Summary of findings of studies of familial cases and controls
Gene Familial Controls RF p RR p
ATM [1] 12/443 2/521 7.1 0.003 2.4 0.0003
(2.7%) (0.8%) (1.6-31) (1.5-3.8)
BRIP1 [2] 9/1,212 2/2,081 7.7 0.002 2.0 0.01
(0.7%) (0.1%) (1.7-36) (1.2-3.2)
PALB2 [3] 10/923 0/1,084 - 0.0004 2.3 0.0025
(1.1%) (0.0%) (1.4-3.9)
PALB2 [4] 3/113 6/2,501 11.1 0.005 NA
(2.7%) (0.2%) (2.8-44)
CHEK2 [5] 55/1,071 18/1,620 4.6 0.00000 1.7 0.0001
(5.1%) (1.1%) (2.7-8) (1.3-2.2)
RFrepresents the relative frequency of mutations in familial cases versus controls. RR represents the estimated effect of carrying a mutation on the
average woman from fitting a multiplicative polygenic model. Confidence intervals for RF and RR are shown in parentheses.Page 3 of 7
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are likely to be associated with a high absolute risk of breast
cancer. That is, these gene mutations are associated with a
high ‘penetrance’ when detected in this context. This inter-
pretation is clinically important, and would justify testing for
these mutations in multiple-case breast cancer families such
as those seen by cancer family genetics services.
The reason for carriers with a strong family history being at
high absolute risk is that a woman’s family history provides an
estimate of her polygenic risk. As a group, women with a
strong family history will be distributed towards the upper end
of the polygenic risk scale (Figures 2 and 3). Multiplying their
polygenic risk, which is two if not more times population risk,
by the factor RR will leave this group of women at
considerable absolute risk. This may even be as high as for
women with a BRCA2 mutation (Figure 4, and see below).
The need for modelling to compensate for
ascertainment
If a risk factor for breast cancer clusters in families, then the
breast cancer cases it produces will also tend to cluster in
families. It follows that genetic risk factors, which are familial
by definition, will be more frequent in women from families
with multiple breast cancers through two effects: their
association with breast cancer per se; and their association
with familial breast cancer in particular.
Consider a rare mutation whose presence doubles the risk of
breast cancer relative to the general population. It will be
Available online http://breast-cancer-research.com/content/10/3/208
Figure 2
Under the multiplicative polygenic model and the logistic model for
lifetime risk of breast cancer, risk is assumed to be due to the
multiplicative actions of many ‘polygenes’ that are assumed to have a
normal distribution across the population. The relative frequency is
indicated by the solid blue line scaled to the left-hand vertical axis. The
lifetime risk (cumulative risk to age 75 years) for women in the general
population (assumed to be, on average, 11%) increases logistically, as
indicated by the solid black line scaled to the right-hand vertical axis.
For women with a strong family history, their polygene distribution is
shifted to the right by a little more than one standard deviation such
that they have, on average, a three-fold increased risk. Their relative
frequency is indicated by the dotted red line scaled to the left-hand
vertical axis.
Figure 3
Under the multiplicative polygenic model and the logistic model for
lifetime risk of breast cancer (Figure 2), for women in the general
population the relative frequency as a function of lifetime risk is
indicated by the solid blue line. For women with a strong family history,
their relative frequency as a function of lifetime risk is indicated by the
dashed red line.
Figure 4
Under the multiplicative polygenic model and the logistic model for
lifetime risk of breast cancer (Figure 2), the distribution of lifetime risk is
shown as a function of the cumulative proportion of the population. For
the great majority of women in the population (indicated by the solid
blue line), their lifetime risk is low (for example, 70% have a lifetime risk
below the population average of 11%) and less than 10% have a
lifetime risk in excess of 40%. For randomly selected women with a
genetic variant associated with, on average, a 2-fold increased risk
(indicated by the dashed blue line), the median lifetime risk is about the
average population risk and about one-quarter have a lifetime risk in
excess of 40%. For women with a strong family history equivalent to a
3-fold increased risk (indicated by the solid red line), nearly 80% are
above average population risk and nearly half have a lifetime risk in
excess of 40%. For those with a strong family history who also have a
genetic variant associated with, on average, a 2-fold increased risk
(indicated by the dashed red line), 90% are above population average
risk and over 70% have a lifetime risk in excess of 40%.approximately four times more common in women who are
affected and have an affected first-degree relative: the ratio is
squared [7]. When a study design defines family history by a
stronger definition, the relationship between RR and relative
frequency of the variants (RF) is likely to be more than a power
of two. This is consistent with the pairs of estimates of RF and
RR shown for mutations in ATM, BRIP1 and CHEK2 in Table 1.
Polygenic risk for breast cancer
There is a second complicating effect of family history. On a
population basis, the observed risk to first-degree relatives of
women with breast cancer is approximately double that of
women without a family history; that is, the familial relative risk
(FRR) is approximately 2, even after adjusting for standard
environmental risk factors [8,9]. Explaining this via the 50% of
genetic material such relatives share requires that the shared
familial risk factors must have large risk ratios [10-12]. For
example, our calculations (Additional file 1) suggest that for a
variant with a minor allele frequency (MAF) of 1% (and
therefore present in 2% of women) the per-allele odds ratio
would need to be 250 to achieve an FRR of 2, which would
dwarf the increased risk associated with any single variant so
far detected [13-15]. Variants that are rare (as are all known
‘high-risk’ mutations) would require even higher odds ratios.
Therefore, it is widely believed that there is a ‘polygenic’
contribution to breast cancer risk, made up of many common
variants of modest risk, which multiply together to produce an
individual’s total relative risk for the carrier [16]. After allowing
for known high risk variants (for which we assumed a total
MAF of 0.25% and a typical odds ratio of 20) a multiplicative
model would require 250 common variants, each with an
odds ratio near 1.24 per allele and a MAF of 30%, to
generate an FRR of 2.
Recent genome-wide scans have identified common genetic
markers associated with breast cancer risk [14,15]. The
effects of individual markers are small, so that even under the
multiplicative polygenic model the combined effect of those
markers identified to date explains less than 4% of the
polygenic variance [14]. Regardless of the particular mixture
of variant numbers and their effect sizes, the overall polygenic
risk would need to increase by approximately 4.8-fold per
standard deviation in order to explain the observed FRR.
Under this model, 43% of all cases would be in the highest
10%, and 63% in the top 20%, of polygenic risk. In
comparison, only 2.5% of cases would be expected to carry
high-risk variants. Of critical interest is that recalculating the
FRR after removing the high-risk variants suggests that the
FRR will be only slightly reduced, to 1.93. For comparison, in
early onset breast cancer where the FRR is greater, the FRR
is found empirically to reduce by only 20% after exclusion of
known BRCA1 and BRCA2 mutation carriers [17].
Since most of the FRR remains after the effects of known
‘high-risk’ breast cancer genes have been discounted, the
polygenic risk estimated from family history is largely
independent of the results of testing for specific genetic risk
factors. It is reasonable to describe the relationship between
the various risk measures as: Absolute risk = (Measured
genetic relative risk) × (Polygenic risk estimated from family
history). Here absolute risk can be thought of as the
cumulative risk at a given age, and the relative risk is in the
sense a, and the polygenic risk is centred on the average
population risk for that age.
‘Low risk’ genes in familial cases: clinically
relevant alleles?
Traditional epidemiology emphasises that the greatest
benefits to the population come from interventions that
decrease risk factors across the bulk of the population, rather
than targeting a small number of individuals at extreme risk.
This paradigm depends on the availability of a low-cost
intervention with no or minimal negative effects, such as
efforts at reducing the prevalence of smoking. However, there
are no such interventions addressing breast cancer risk in the
population.
With respect to women at high or increased risk due to
known or likely genetic factors, possible options include
chemoprevention and prophylactic surgery (oophorectomy
and/or mastectomy). Even enhanced surveillance has costs in
respect of false positives and the expense of newer radio-
logical techniques appropriate for younger women. There is
also potential for enhanced radiation effects of mammo-
graphy on cancer risks, especially for women with a strong
cancer family history who as a group may be genetically more
vulnerable to radiation. Detection of the known genetic
factors themselves has considerable cost with present tech-
nology and the rarity of high-risk mutations in the known sus-
ceptibility genes make general population screening impractical.
Consequently, screening for genetic risk factors, at least for
the near future, will continue to typically be available only to
those women identified as having a priori high risk due to
their personal and/or family history, except perhaps in sub-
populations in which founder mutations are frequent. How-
ever, these women will be at higher than average risk regard-
less of the test findings, due to the approximate indepen-
dence of FRR and known genetic risk factors (see the
previous section).
Moreover, if the multiplicative model applies, genes of modest
relative risk will, in fact, dramatically increase the absolute risk
in the context of a family history, due to multiplication by the
polygenic risk implied by their family history. For example, a
relative risk of 2.5 multiplied by the FRR for a single affected
first-degree relative would become a 5-fold increase in risk.
For a woman with a more severe family history, such as one
including early onset disease, the absolute risk for a woman
who carries a risk-variant of ATM,  BRIP1,  PALB2 and
CHEK2 may have an absolute lifetime risk approaching 50%
or more (Figure 4; in this regard, it is interesting to note the
Breast Cancer Research    Vol 10 No 3 Byrnes et al.
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based study of a specific mutation (c.7271T>G) in ATM [18]
and the recent report of two mutations in PALB2 tracking
with disease in multiple-case breast cancer families
ascertained in Montreal [19]). This extent of increased risk is
comparable to the average increased risk of about 10-fold,
and lifetime risk of around 40%, for women who carry a
mutation in BRCA2  [20]. Hence, there are immediate
implications for genetic counselling, and possible genetic
testing for the ATM, PALB2, BRIP1 and CHEK2 genes, of
women from families with a strong history of breast cancer
found not to carry a germline mutation in BRCA1 or BRCA2.
If the model is wrong…
We and others [16] have assumed a multiplicative model and
the logistic model for lifetime risk of breast cancer (Additional
file 1) to combine the effects of many risk-increasing genetic
variants (Figures 2 and 3). This appeared to be the best fit to
some available population-based data [21], although the
power to distinguish models is limited, equivalent to testing
for interaction effects. Many other models are possible, but
the most obvious alternative is one where the effects add
rather than multiply. The consequences of fitting an additive
model would be very different for most women (the
relationship between groups C and D in Figure 1); the
estimated risk for women without a family history will be
greater than if a multiplicative model is assumed; when this
larger risk difference is added to the risk implied by family
history, the absolute risk for the observed women (who have
a strong family history) should be approximately the same as
under the multiplicative model.
That is, for women with a strong family history the conclusion
will be little different no matter what model is fitted. This is
because, while the effect sizes estimated from the quoted
studies of ATM, BRIP1, PALB2 and CHEK2 depend on the
model, any fitted model will generally give reasonably good
predictions for the observed subset of data on which it was
trained. In other words, predictions for women in group A of
Figure 1 will be only weakly dependent on the model, since
they are observed directly. The implications of model choice
are seen mainly in groups C and D, but these women are less
likely to present for genetic counselling.
Discussion
The studies we have discussed all investigated the role of
genetic variants for modifying the risk of breast cancer in
women with affected relatives. This selection of women for
molecular screening was primarily due to practical issues, but
it also coincides with the context in which the information will
be most immediately used: in counselling women who are
seeking to establish their personal risk of breast cancer given
the history of cancer in their relatives.
The authors of these studies have estimated the multiplicative
risk increase associated with having a mutation when all other
factors are held constant. They have shown, but not
recognised, that while the implied absolute risk for the
average carrier in the population is not substantial, it may be
very high for carriers detected through testing women with a
strong family history. The same argument can be applied in
other settings, such as for carriers of ‘high-risk’ mutations in
genes like BRCA1 and BRCA2 [21], and for risks associated
with one or more of the common ‘low-risk’ variants identified
by recent genome wide association studies [14,15]. Even
though they had not studied unselected cases, and in
particular had not studied cases without a strong family
history (group C in Figure 1), the authors have focused on
implications for average women. That is, they have tried to
conduct a comparison of mutation frequencies between
group A+C and group B+D even though the mutation
frequency in group A+C was unknown. To do so it is
necessary to invoke models of familial risks to account for the
fact that only familial cases had been studied (that is, to make
an adjustment for ascertainment; see above). They chose to
consider a multiplicative polygenic model [6,16,22]. No
matter what genetic models had been fitted, however, the
predictions for women with a strong family history will be
generally the same provided the models gave reasonable fits.
Note that these studies do not have the necessary data to
test how good the fit was for women without a strong family
history (groups C and D of Figure 1), because they were not
included in the cases who underwent testing.
It is a concern that by highlighting in the abstracts of their
papers their model-dependent risk ratio estimates of 2.4 for
ATM mutations, 2.0 for BRIP1 mutations, 2.3 for PALB2
mutations, and 1.7 for the CHEK2 mutation, even having in
the title of two of these papers the expression ‘low-
penetrance’ [2,5], genetic counsellors may be misled and
disregard the significance of ATM,  BRIP1,  PALB2 and
CHEK2 mutations in the setting where they might be found
and have considerable consequence. Since counsellors and
clinicians typically see only women with a strong family
history, the increased risk to an average woman is irrelevant
unless interpreted as above in terms of her family history as a
surrogate for her polygenic risk status.
These studies have used data from familial cases to estimate
the increase in risks for women in general, most of whom do
not have a strong family history of breast cancer. The danger
is that the results will be interpreted in the epidemiological
sense a above as meaning that carriers are at about twice
population risk, whereas they should be interpreted in the
sense b as multiplying the polygenic risk implied by family
history. The clinical importance of this important work to
women who seek genetic counselling is being undersold.
There is some limited information on the prevalence of these
mutations in women with breast cancer who do not have a
strong family history (group C in Figure 1), or who are
unselected for family history (group A+C), but none for
Available online http://breast-cancer-research.com/content/10/3/208
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test of the multiplicative model would be to see if the
mutation frequency was increased in group A relative to
group B by the same degree (as predicted by the fitted
polygenic model). One large international case-control study
of the 1100delC CHEK2 mutation [23] found the overall
prevalence to be 1.9% for cases and 0.7% for controls. Note
that the estimated odds ratio, 2.3 (95% confidence interval
1.7 to 3.2), is consistent with the indirect estimate of 1.7
(95% confidence interval 1.3 to 2.2) from the multiplicative
polygenic modelling of familial cases and controls, though
this of itself does not necessarily justify the model
assumptions.
For PALB2, the Finnish founder mutation was found in 18 of
1,918 (0.9%) cases unselected for family history [4], in
between the 3 of 113 (2.7%) familial cases and 6 of 2,501
(0.2%) controls. Similarly, a French-Canadian founder muta-
tion was found in 2 of 356 (0.6%) unselected, but early
onset, cases compared with 1 of 50 (2%) familial cases and
0 of 6,442 (0%) newborns [24]. The numbers of PALB2
founder mutation carriers above are too small to make precise
or even meaningful estimates of risk from standard case-
control comparisons, although modified segregation analyses
of data from the families of case-carriers can be used to
estimate risk for carrier families found from testing unselected
cases [25], as has recently been demonstrated for these
founder mutations [26]. This also raises the possibility that
risks could be mutation specific, and highlights that the
published studies are estimating the average risk over all
mutations identified in the context of the sampled subjects, so
these penetrance estimates may depend on the population,
family history, age at onset and other considerations.
Mutations that are rare in the population, but not uncommon
in the familial setting, may be very important for determining
some people’s risk. The pursuit of common breast cancer risk
variants in candidate genes is proving to be frustrating (for
example, [13]). The recent genome wide scans of tens of
thousands of cases and controls suggest the strengths of
association for common risk variants may be very small
[13,15]. The pursuit of uncommon variants using case-control
designs is problematic due to the need for genotyping even
larger numbers of controls, due to their rarity in the
population. Nevertheless, the effects of the uncommon but
causal variants may be much greater.
We suggest, therefore, that there is a role for the continuing
investigation of uncommon, or rare variants of as yet un-
quantified effect (sometimes referred to as ‘unclassified
variants’), and perhaps reconsidering candidate genes pre-
viously studied for common variants, including those from this
new perspective [27], and of linkage analyses of large
multiple-case families now shown not to be segregating
known high-risk mutations. That is, future understanding of
breast cancer susceptibility genes of consequence for
individuals may continue to come from studies of related
individuals, given that even very large studies of unrelated
cases and controls currently appear to be able to identify only
those genetic factors that are associated with little impact on
individual risk [14,15].
In the quest to discover genetic variants that influence
disease risk, it is important to remember what risk estimates
mean for the individual carrier. Association studies, where
cases and controls are screened for genetic variants, usually
present findings as multiplicative relative risks; that is, the risk
for carriers divided by that for persons similar in every way
except carriage of the variant. There are complications if
cases are selected due to having a family history because
these familial cases may be enriched for carriers due to the
variant’s effect on risk for both the individual and their
relatives. For an individual with high pre-test risk, variants that
are ‘low risk’ for the average person may become important.
Pre-test risk is highly variable, best predicted by family history
and typically elevated in those seeking genetic counselling.
We considered women who present for counselling at breast
cancer family clinics, typically because of their family history,
in the context of recent studies of ATM, BRIP1, PALB2 and
CHEK2. We argue that detection of mutations in these
genes may be of considerable clinical consequence in terms
of absolute breast cancer risk (that is, penetrance) for women
with a strong family history.
Conclusion
Rather than being universally ‘low-penetrance’, mutations in
genes like ATM, BRIP1, PALB2 and CHEK2 that are known
to interact with BRCA1 and BRCA2 may be associated with
a ‘high risk’ for a subset of women. This subset is likely to be
enriched for those with a personal or strong family history of
breast cancer, especially if it is of early onset. Therefore,
mutation testing of these genes for such women may be as
clinically relevant as is mutation testing for BRCA1 and
BRCA2.
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based on a logistic model for lifetime risk of breast cancer, of
the FRR resulting from a given number of alleles of specified
per-allele odds-ratio and allele frequency. It also contains
calculations of the number of SNPs required to produce a
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